Citi backs AstraZeneca sentiment boost after Etcamah wins accelerated FDA approval Proactive Investors (US) 18h
Etcamah® (camizestrant) in combination with a CDK4/6 inhibitor approved in the US for 1st-line advanced HR-positive breast cancer Business Wire (Press Release) 3d
Guardant health announces landmark FDA approval of Guardant360® cdx as companion diagnostic for AstraZeneca’s Etcamah™ (camizestrant) in advanced breast cancer Business Wire (Press Release) 3d